Phosphoinositide 3-OH kinases (PI(3)Ks) are important lipid signaling enzymes and exciting drug targets for a number of human diseases. The first, much anticipated crystal structure of the delta isoform of PI(3)K provides surprising new insights into the selectivity of inhibitors for this versus other PI(3)K isoforms and facilitates the design of improved drugs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
02 March 2010
In the version of this article initially published, there was an error in the chemical structure of IC87114 that arose from the coordinates used to generate Figure 1a. The corrected structure has been deposited by Berndt et al. to the Protein Data Bank (PDB code 2X38). Figure 1a and the PDB code in the figure legend have been corrected in the HTML and PDF versions of the article.
References
Berndt, A. et al. Nat. Chem. Biol. 6, 117–124 (2010).
van Montfort, R.L.M. & Workman, P. Trends Biotechnol. 27, 315–328 (2009).
Liu, P., Cheng, H., Roberts, T.M. & Zhao, J.J. Nat. Rev. Drug Discov. 8, 627–644 (2009).
Cantley, L.C. Science 296, 1655–1657 (2002).
Crabbe, T., Welham, M.J. & Ward, S.G. Trends Biochem. Sci. 32, 450–456 (2007).
Workman, P., Clarke, P.A., Raynaud, F.I. & van Montfort, R.L.M. Cancer Res. (in the press).
Walker, E.H., Perisic, O., Ried, C., Stephens, L. & Williams, R.L. Nature 402, 313–320 (1999).
Walker, E.H. et al. Mol. Cell 6, 909–919 (2000).
Knight, Z.A. et al. Cell 125, 733–747 (2006).
Huang, C.-H. et al. Science 318, 1744–1748 (2007).
Sadhu, C., Masinovsky, B., Dick, K., Sowell, C.G. & Staunton, D.E. J. Immunol. 170, 2647–2654 (2003).
Williams, O. et al. Chem. Biol. (in the press).
Folkes, A.J. et al. J. Med. Chem. 51, 5522–5532 (2008).
Raynaud, F.I. et al. Mol. Cancer Ther. 8, 1725–1738 (2009).
Vogt, P.K., Gymnopoulos, M. & Hart, J.R. Curr. Opin. Genet. Dev. 19, 12–17 (2009).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
P.W. and R.L.M.M. are employees of The Institute of Cancer Research, which has a commercial interest in the development of PI(3)K inhibitors, and operates a rewards-to-inventors scheme. P.W. has been involved in a commercial collaboration with Yamanouchi (now Astellas Pharma) and with Piramed Pharma, and intellectual property arising from the program has been licensed to Genentech. P.W. was a scientific founder of, consultant to, and Scientific Advisory Board member of Piramed Pharma; is a scientific founder of, consultant to, and Scientific Advisory Board member and Main Board member of Chroma Therapeutics; and was formerly an employee of AstraZeneca. R.L.M.M. is a former employee of Astex Therapeutics.
Rights and permissions
About this article
Cite this article
Workman, P., van Montfort, R. Revealing the delta lady. Nat Chem Biol 6, 82–83 (2010). https://doi.org/10.1038/nchembio.305
Issue Date:
DOI: https://doi.org/10.1038/nchembio.305
This article is cited by
-
Erratum: Corrigendum: Revealing the delta lady
Nature Chemical Biology (2010)
